GSK-LSD1 2HCl

Catalog No.S7574 Batch:S757401

Print

Technical Data

Formula

C14H22Cl2N2
Molecular Weight 289.24 CAS No. 2102933-95-7
Solubility (25°C)* In vitro DMSO 57 mg/mL (197.06 mM)
Water 57 mg/mL (197.06 mM)
 
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
2.85mg/ml Taking the 1 mL working solution as an example, add 50 μL of 57 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.47mg/ml Taking the 1 mL working solution as an example, add 50 μL of 9.4 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).
Targets
LSD1 [1]
(Cell-free assay)
16 nM
In vitro

GSK-LSD1 induces gene expression changes in cancer cell lines with average EC50 of < 5 nM and inhibits cancer cell line growth with average EC50 of < 5 nM. [1]
In vivo

GSK-LSD1, a highly selective inhibitor of KDM1A, significantly inhibits thyroid cancer progression and enhances the sensitivity of thyroid cancer to chemotherapy.

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    U2OS cells

  • Concentrations

    200 μM

  • Incubation Time

    12 h

  • Method

    Cells were treated with indicated concentration of drug for 12 h.

Selleck's GSK-LSD1 2HCl has been cited by 21 publications

Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC [ Cell Death Dis, 2023, 10.1038/s41419-023-06238-5] PubMed: 37923740
Insect immunity and its interactions with microorganisms and parasitoids [ Front Immunol, 2023, ] PubMed: none
Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation [ Cell Death Differ, 2022, 10.1038/s41418-022-00983-4] PubMed: 35379950
KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway [ Theranostics, 2022, 12(4):1500-1517] PubMed: 35198054
BmCPV-Derived Circular DNA vcDNA-S7 Mediated by Bombyx mori Reverse Transcriptase (RT) Regulates BmCPV Infection [ Front Immunol, 2022, 13:861007] PubMed: 35371040
BmCPV-Derived Circular DNA vcDNA-S7 Mediated by Bombyx mori Reverse Transcriptase (RT) Regulates BmCPV Infection [ Front Immunol, 2022, 13:861007] PubMed: 35371040
Lysine specific demethylase 1 inhibitor alleviated lipopolysaccharide/D-galactosamine-induced acute liver injury [ Eur J Pharmacol, 2022, 932:175227] PubMed: 36007605
ZKSCAN5 Activates VEGFC Expression by Recruiting SETD7 to Promote the Lymphangiogenesis, Tumour Growth, and Metastasis of Breast Cancer [ Front Oncol, 2022, 12:875033] PubMed: 35600335
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma [ Cancer Chemother Pharmacol, 2022, 89(5):643-653] PubMed: 35381875
Eupalinilide B as a novel anti-cancer agent that inhibits proliferation and epithelial-mesenchymal transition in laryngeal cancer cells [ J Int Med Res, 2022, 50(1):3000605211067921] PubMed: 35098772

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.